Three-Year Delays Seen in First Referral for Diabetic Retinopathy

This article originally appeared here.
Share this content:
Three-Year Delays Seen in First Referral for Diabetic Retinopathy
Three-Year Delays Seen in First Referral for Diabetic Retinopathy

FRIDAY, July 15, 2016 (HealthDay News) -- An average delay of 3.1 years for an initial diabetes eye exam was found in a recent Australian study. The findings were published online in a letter to the editor June 27 in Clinical & Experimental Ophthalmology.

Brigitte M. Papa, M.D., from the University of Melbourne in Australia, and colleagues examined current general practitioner (GP) management practices for DR screening in a cross-sectional survey of 598 GPs in Victoria. The survey comprised 12 questions relating to DR screening. Data were included from 198 responses to the survey, of which 175 were complete.

The researchers found that there was a mean period of 3.1 years between diabetes diagnosis and first eye referral. Overall, 53 percent of GPs reported that they referred newly diagnosed individuals for an eye check at the time of diagnosis; 23 percent referred patients at one year or more after initial diagnosis. Ninety-seven percent of GPs reported referring patients with type 2 diabetes for DR screening at least biennially. However, only 55 and 39 percent of GPs verified patient uptake of the first eye referral and confirmed receipt of a report from the eye health professional following the first eye assessment, respectively.

"This study signals the need for better systems of care to support DR screening and, ultimately, improve long-term visual outcomes for persons with diabetes," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

SABCS: Artificial Intelligence May Aid Doctors in Breast Cancer Care

SABCS: Artificial Intelligence May Aid Doctors in Breast ...

'Watson Oncology' agreed with doctors 90 percent of the time in many cases, researchers find

SABCS: Scalp-Cooling System Can Reduce Chemo-Related Hair Loss

SABCS: Scalp-Cooling System Can Reduce Chemo-Related Hair Loss

Devices reduce blood flow to hair follicles during chemotherapy treatments

SABCS: Aromatase Inhibitors Tied to Reduced Endothelial Function

SABCS: Aromatase Inhibitors Tied to Reduced Endothelial Function

Women on aromatase inhibitors exhibit less elasticity in their blood vessels

is free, fast, and customized just for you!

Already a member?

Sign In Now »